EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause

Goran Bokan iD, Tanja Glamočanin, Zoran Mavija, Bojana Vidović, Ana Stojanović, Einar S Björnsson, Vesna Vučić iD

Pharmaceuticals · 10.08.2023 · 16 (8) · 1129

DOI: 10.3390/ph16081129 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pharmaceuticals, online erschienen am 10.08.2023. Verfasst von Goran Bokan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Clinic, Department of Gastroenterology and Hepatology, University Clinical Centre of the Republic of Srpska, 78000 Banja Luka, Repu…. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: COST Action CA17112—Prospective European Drug Induced Liver Injury Network (ProEuroDILINet), Ministry of Science, Technological Development, and Innovation of the Republic of Serbia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herb-induced liver injury (HILI) caused by herbal supplements, natural products, and products used in traditional medicine are important for differential diagnoses in patients with acute liver injury without an obvious etiology. The root of Withania somnifera (L.) Dunal, commonly known as ashwagandha, has been used in Ayurvedic medicine for thousands of years to promote health and longevity. Due to various biological activities, ashwagandha and its extracts became widespread as herbal supplements on the global market. Although it is generally considered safe, there are several reported cases of ashwagandha-related liver injury, and one case ended with liver transplantation. In this paper, we review all reported cases so far. Additionally, we describe two new cases of ashwagandha hepatotoxicity. In the first case, a 36-year-old man used ashwagandha capsules (450 mg, three times daily) for 6 months before he developed nausea, pruritus, and dark-colored urine. In the second case, a 30-year-old woman developed pruritus after 45 days of using ashwagandha capsules (450 mg). In both cases, serum bilirubin and liver enzymes (aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase (ALP) were increased. The liver injury pattern was hepatocellular (R-value 11.1) and mixed (R-value 2.6), respectively. The updated Roussel Uclaf Causality Assessment Method (RUCAM) (both cases with a score of seven) indicated a “probable” relationship with ashwagandha. Clinical and liver function improvements were observed after the discontinuation of ashwagandha supplement use. By increasing the data related to ashwagandha-induced liver injury, these reports support that consuming ashwagandha supplements is not without its safety concerns.

Schlagwörter

Stichwörter der Autor:innen

ashwagandhahepatotoxicityherb-induced liver injury (HILI)liver injuryupdated RUCAM

Autor:innen und Institutionen

  • Internal Medicine Clinic, Department of Gastroenterology and Hepatology, University Clinical Centre of the Republic of Srpska, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina.
  • Faculty of Medicine, University of Banja Luka, 78000 Banja Luka, Republic of Srpska, Bosnia and Herzegovina.
  • Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
  • Bežanijska Kosa Clinical Hospital Center, 11000 Belgrade, Serbia.
  • Landspitali University Hospital, 101 Reykjavik, Iceland.
  • Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.

ORCID-Profile: Goran Bokan, Vesna Vučić

Förderung

  • COST Action CA17112—Prospective European Drug Induced Liver Injury Network (ProEuroDILINet)
  • Ministry of Science, Technological Development, and Innovation of the Republic of Serbia

Zitieren

APA

Bokan, G., Glamočanin, T., Mavija, Z., Vidović, B., Stojanović, A., Björnsson, E. S., & Vučić, V. (2023). Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause. Pharmaceuticals, 16(8), 1129. https://doi.org/10.3390/ph16081129

Vancouver

Bokan G, Glamočanin T, Mavija Z, Vidović B, Stojanović A, Björnsson ES, et al. Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause. Pharmaceuticals. 2023;16(8):1129. doi:10.3390/ph16081129

BibTeX
@article{Bokan2023,
  author = {Bokan, Goran and Glamočanin, Tanja and Mavija, Zoran and Vidović, Bojana and Stojanović, Ana and Björnsson, Einar S and Vučić, Vesna},
  title = {Herb-Induced Liver Injury by Ayurvedic Ashwagandha as Assessed for Causality by the Updated RUCAM: An Emerging Cause},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {8},
  pages = {1129},
  doi = {10.3390/ph16081129}
}
Kostenlos starten →